All cause mortality in the Swiss HIV cohort study from 1990 to 2001 in comparison with the Swiss population

AIDS

Volumn 18, Issue 13, 2004, Pages 1835-1843

  Keiser, Olivia ^a,f   Taffé, Patrick ^a   Zwahlen, Marcel ^b   Battegay, Manuel ^c   Bernasconi, Enos ^d   Weber, Rainer ^e   Rickenbach, Martin ^a  

^a Swiss HIV Cohort Study Data Center   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

^c UNIVERSITY HOSPITAL BASEL   (Switzerland)

^d Ospedale Civico Lugano   (Switzerland)

^e UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^f LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Demography; Drug users; Epidemiology; Life tables; Mortality

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; GENDER; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; INTRAVENOUS DRUG ABUSE; LIFE TABLE; LYMPHOCYTE COUNT; MALE; MORTALITY; MULTICENTER STUDY; POPULATION RESEARCH; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; STANDARDIZATION; STATISTICAL SIGNIFICANCE; SURVIVAL; SWITZERLAND; T LYMPHOCYTE; VIRUS TRANSMISSION;

ADOLESCENT; ADULT; AGED; CAUSE OF DEATH; COHORT STUDIES; CONFIDENCE INTERVALS; HIV INFECTIONS; HUMANS; LIFE TABLES; MIDDLE AGED; PROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL ANALYSIS; SWITZERLAND;

EID: 4444381003     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200409030-00013     Document Type: Article

References (32)

1. Egger M, Hirschel B, Francioli P, Sudre P, Wirz M, Flepp M, et al. Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study. Swiss HIV Cohort Study. BMJ 1997; 315:1194-1199.
2. Mocroft A, Vella S, Benfield TL, Chiesi A, Miller V, Gargalianos P, et al. Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group. Lancet 1998; 352:1725-1730.
3. Palella FJ, Delaney KM, Moorman A, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998; 339:853-860.
4. Naghten AD, Hanson DL, Jones JL, Dworkin MS, Ward JW. Effects of antiretroviral therapy and opportunistic illness primary chemoprophylaxis on survival after AIDS diagnosis. Adult/Adolescent Spectrum of Disease Group. AIDS 1999; 13:1687-1695.
5. Lewden C, Raffi F, Chene C, Sobel A, Leport C. Mortality in a cohort of HIV-infecfed adults started on a protease inhibitor-containing therapy: standardization to the general population. APROCO Study Group. J Acquir Immune Defic Syndr 2001; 26:480-482.
6. Jäggy C, Overbeck J, Ledergerber B, Schwarz C, Baumgartner S, Egger M, et al. Mortality in the Swiss HIV Cohort Study (SHCS) and the Swiss general population. Lancet 2003; 362:877-878.
7. Chiang CL. The Life Table and its Applications. Malabar (Florida): Robert E Krieger Publishing Company; 1984.
8. BAG. Rapport OFSP 2001/VIH et Sida. Available at www. admin.ch/bag/infekt/surv/aids/f
9. Rickenbach M, Keiser O, Taffé P, Francioli P. L'étude suisse de cohorte VIH. Médecine et Hygiène 2003; 61:719-723.
10. Ledergerber B, van Overbeck J, Egger M, Lüthi R. The Swiss HIV Cohort Study: rationale, organization and selected baseline characteristics. Soz Präventivmed 1994; 39:387-394.
11. Human mortality database. University of California, Berkley (USA), and Max Planck Institute for Demographic Research (Germany). Available at www.mortality.org.
12. Zurn P, Taffé P, Rickenbach M, Denthine JP. The Social Cost of HIV Infection in Switzerland. Lausanne: IEMS; 2001. Study supported by the Control and Research Commission on AIDS (substudy 99-7431) and the Swiss National Science Foundation (substudy 3346.062048.00). Available at: http://www.hec.unil. ch/jdanthine/other%20reports/hiv.pdf
13. Bassetti S, Battegay M, Furrer H, Rickenbach M, Flepp M, Kaiser L, et al. Why is highly active antiretroviral therapy (HAART) not prescribed or discontinued? Swiss HIV Cohort Study. J Acquir Immune Defic Syndr 1999; 21:114-119.
14. Bundesamt für Statistik. Statistisches Jahrbuch 2003. Zürich: Verlag Neue Zürcher Zeitung; 2003.
15. Egger M, May M, Chene C, Phillips AN, Ledergerber B, Dabis F, et al. ART Cohort Collaboration. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 2002; 360:119-129.
16. Von Overbeck J, Egger M, Smith GD, Schoep M, Ledergerber B, Furrer H, et al. Survival in HIV infection: do sex and category of transmission matter? Swiss HIV Cohort Study. AIDS 1994; 8:1307-1313.
17. CASCADE Collaboration. Determinants of survival following HIV-1 seroconversion after the introduction of HAART. Lancet 2003; 362:1267-1274.
18. Van Asten LC, Boufassa F, Schiffer V, Brettle RP, Robertson JR, Hernandez Aguado I, et al. Limited effect of highly active antiretroviral therapy among HIV-positive injecting drug users on the population level. Eur J Public Health 2003; 13:347-349.
19. Perez-Hoyos S, del Amo J, Muga R, del Romero J, Garcia de Olalla P, Guerrero R, et al. GEMES (Spanish Multicenter Study Group of Seroconverters). Effectiveness of highly active antiretroviral therapy in Spanish cohorts of HIV seroconverters: differences by transmission category. AIDS 2003; 17:353-359.
20. Carrieri MP, Moatti JP, Vlahov D, Obadia Y, Reynaud-Maurupt C, Chesney M. Access to antiretroviral treatment among French HIV infected injection drug users: the influence of continued drug use. MANIF 2000 Study Group. J Epidemiol Community Health 1999; 53:4-8.
21. Celentano DD, Galai N, Sethi AK, Shah NG, Strathdee SA, Vlahov D, et al. Time to initiating highly active antiretroviral therapy among HIV-infected injection drug users. AIDS 2001; 15:1707-1715.
22. Strathdee SA, Palepu A, Cornelisse PG, Yip B, O'Shaughnessy MV, Montaner JS, et al. Barriers to use of free antiretroviral therapy in injection drug users. JAMA 1998; 280:547-549.
23. Bouhnik AD, Chesney M, Carrieri P, Gallais H, Moreau J, Moatti JP, et al. MANIF 2000 Study Group. Monadherence among HIV-infected injecting drug users: the impact of social instability. J Acquir Immune Defic Syndr 2002; 31(Suppl 3):149-153.
24. Carrieri MP, Chesney MA, Spire B, Loundou A, Sobel A, Lepeu G et al. Failure to maintain adherence to HAART in a cohort of French HIV-positive injecting drug users. Int J Behav Med 2003; 10:1-14.
25. Palepu A, Tyndall M, Yip B, O'Shaughnessy MV, Hogg RS, Montaner JS. Impaired virologic response to highly active antiretroviral therapy associated with ongoing injection drug use. J Acquir Immune Defic Syndr. 2003; 32:522-526.
26. Bica I, McGovern B, Dhar R, Stone D, McGowan K, Scheib R, et al. Increasing mortality due to end stage liver disease on patients with human immunodeficiency virus infection. Clin Infect Dis 2001;32:492-497.
27. Louie JK, Hsu LC, Osmond DH, Katz MH, Schwarcz SK. Trends in causes of death among persons with acquired immunodeficiency syndrome in the era of highly active antiretroviral therapy, San Francisco, 1994-1998. J Infect Dis. 2002; 186:1023-1027.
28. Macias J, Melugizo I, Fernandez-Rivera FJ, Garcia-Garcia A, Mira JA, Ramos-Rivera JM, et al. Mortality due to liver failure and impact on survival of hepatitis virus infections in HIV-infected patients receiving potent antiretroviral therapy. Eur J Clin Microbiol Infect Dis. 2002; 21:775-781.
29. Rosenthal E, Poiree M, Pradier C, Perronne C, Salmon-Ceron D, Geffray L, et al. Mortality due to hepatitis C-related liver disease in HIV-infected patients in France (Mortavic 2001 study). AIDS 2003; 17:1803-1809.
30. Selik RM, Byers RH Jr, Dworkin MS. Trends in diseases reported on U.S. death certificates that mentioned HIV infection, 1987-1999. J Acquir Immune Defic Syndr 2002; 29:378-87.
31. Web site Swiss HIV Cohort Study. Available at www.shcs.ch.
32. Greub G, Ledergerber B, Battegay M, Grob P, Perrin L, Furrer H, et al. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. Lancet 2000; 356:1800-1805.